The recent article by Liang et al. (2011) , published in Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology) , is highly interesting. Interestingly, the past few years have seen the increasing application of berbamine as an anti-cancer agent in other systemic malignancies besides chronic myeloid leukemia.
For instance, berbamine administration alters the Bcl-2/Bax ratio and mitigates cell migration and thereby augments the anti-proliferative ability of trichostatin A in non-small cell lung cancers (Duan et al., 2010) . Similarly, berbamine inhibits p65 translocation, up-regulates A20 and increases the activation of the GADD45/c-Jun N-terminal kinase (JNK) pathway, thereby enhancing cellular apoptosis in multiple myelomas (Liang et al., 2009a; 2009b) . Similarly, alteration of the nuclear factor-kappa B (NF-κB) pathway results in enhanced apoptosis in lymphomas .
Similarly, the apoptotic ability of chemotherapeutic agents such as doxorubicin and carmofur is markedly enhanced by co-administration of berbamine, as a result of attenuated expression of cdc2/p34 and vascular endothelial growth factor (VEGF) in affected cells (Cheng et al., 2006; Wang S. et al., 2009; Liu et al., 2010) . This results in accentuated G 2 /M cell cycle arrest and reversal of multidrug resistance in MCF-7/ADR breast cancer tissue . Similarly apoptosis in hepatocellular carcinomas is augmented by berbamine-mediated induction of the Fas apoptotic pathway and loss in mitochondrial trans-membrane potential (Wang G.Y. et al., 2007; 2009) .
The above examples clearly illustrate the significant anti-proliferative activity of berbamine and the need for further studies to fully elaborate its anticancer properties. Liu For the Letter to the Editor "Emerging role of berbamine as an anti-cancer agent in systemic malignancies besides chronic myeloid leukemia", we are pleased with the interest in our article (Liang et al., 2011) , and appreciate the insightful comments made by Dr. Kapoor (2012) . He systemically reviewed application of berbamine as an anti-cancer agent during the past few years and found that berbamine also shows anti-cancer activity for other systemic malignancies besides chronic myeloid leukemia. Extensive scrutiny of its molecular targets and mechanism of action in the past few decades has provided important insights. At the cellular level, berbamine exhibits significantly antiproliferative activity, inhibiting the proliferations of leukemia, lymphoma , breast cancer , and hepatocellular carcinoma (Wang et al., 2009) . At the molecular level, berbamine-mediated anti-tumor activity was shown to be involved in PI3K/Akt, nuclear factor-kappaB (NF-κB) , Fas-mediated apoptosis (Wang et al., 2009) , and P-glycoprotein . However, its targets and molecular mechanism of action are still largely elusive. We feel that identification of the direct molecular target of berbamine will account for the diverse biological activities.
